AIM: First-episode psychosis and borderline personality disorder are severe mental disorders that have their onset in youth. Their co-occurrence is clinically well recognized, is associated with significant risks and is complex to treat. Yet, there is no published specific intervention for this problem. This study reports a pilot randomized controlled trial comparing combined specialist first-episode treatment plus specialist early intervention for borderline personality, entitled Helping Young People Early, with specialist first-episode treatment alone. We aimed to evaluate the safety and feasibility of adding early intervention for borderline personality. METHODS: The study investigated the safety of specialist first-episode treatment plus specialist early intervention for borderline personality in relation to deterioration in psychosis, aggression, self-harm and suicidality, and feasibility in relation to the completion of therapy phases. Sixteen patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for first-episode psychosis and borderline personality (four or more DSM-IV criteria) were randomized either to specialist first-episode treatment alone or specialist first-episode treatment plus specialist early intervention for borderline personality and were followed up at the end of treatment and 6 months later. RESULTS: The results showed that it was feasible to recruit and assess a high risk and complex group of patients who were agreeable to study participation. Specialist first-episode treatment plus specialist early intervention for borderline personality was an acceptable and safe treatment. CONCLUSION: A larger-scale randomized controlled trial of early intervention for borderline personality for young first-episode psychosis patients with co-occurring full or subsyndromal borderline personality is warranted.
RCT Entities:
AIM: First-episode psychosis and borderline personality disorder are severe mental disorders that have their onset in youth. Their co-occurrence is clinically well recognized, is associated with significant risks and is complex to treat. Yet, there is no published specific intervention for this problem. This study reports a pilot randomized controlled trial comparing combined specialist first-episode treatment plus specialist early intervention for borderline personality, entitled Helping Young People Early, with specialist first-episode treatment alone. We aimed to evaluate the safety and feasibility of adding early intervention for borderline personality. METHODS: The study investigated the safety of specialist first-episode treatment plus specialist early intervention for borderline personality in relation to deterioration in psychosis, aggression, self-harm and suicidality, and feasibility in relation to the completion of therapy phases. Sixteen patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for first-episode psychosis and borderline personality (four or more DSM-IV criteria) were randomized either to specialist first-episode treatment alone or specialist first-episode treatment plus specialist early intervention for borderline personality and were followed up at the end of treatment and 6 months later. RESULTS: The results showed that it was feasible to recruit and assess a high risk and complex group of patients who were agreeable to study participation. Specialist first-episode treatment plus specialist early intervention for borderline personality was an acceptable and safe treatment. CONCLUSION: A larger-scale randomized controlled trial of early intervention for borderline personality for young first-episode psychosispatients with co-occurring full or subsyndromal borderline personality is warranted.
Authors: Andrew M Chanen; Jennifer K Betts; Henry Jackson; Sue M Cotton; John Gleeson; Christopher G Davey; Katherine Thompson; Sharnel Perera; Victoria Rayner; Sinn Yuin Chong; Louise McCutcheon Journal: Can J Psychiatry Date: 2021-02-12 Impact factor: 5.321
Authors: Ole Jakob Storebø; Jutta M Stoffers-Winterling; Birgit A Völlm; Mickey T Kongerslev; Jessica T Mattivi; Mie S Jørgensen; Erlend Faltinsen; Adnan Todorovac; Christian P Sales; Henriette E Callesen; Klaus Lieb; Erik Simonsen Journal: Cochrane Database Syst Rev Date: 2020-05-04
Authors: Christina W Slotema; Jan Dirk Blom; Marieke B A Niemantsverdriet; Iris E C Sommer Journal: Front Psychiatry Date: 2018-07-31 Impact factor: 4.157
Authors: S M Cotton; M Berk; A Watson; S Wood; K Allott; C F Bartholomeusz; C C Bortolasci; K Walder; B O'Donoghue; O M Dean; A Chanen; G P Amminger; P D McGorry; A Burnside; J Uren; A Ratheesh; S Dodd Journal: Trials Date: 2019-11-28 Impact factor: 2.279
Authors: Mie Sedoc Jørgensen; Ole Jakob Storebø; Jutta M Stoffers-Winterling; Erlend Faltinsen; Adnan Todorovac; Erik Simonsen Journal: PLoS One Date: 2021-01-14 Impact factor: 3.240